Cairo – Mubasher: The consolidated net profits after tax of Egyptian International Pharmaceutical Industries (EIPICO) hit EGP 509.28 million in the first half (H1) of 2023, versus EGP 304.38 million in H1-22, including non-controlling equity.
The sales enlarged to EGP 2.26 billion in January-June 2023 from EGP 1.73 billion during the same period a year earlier, according to the consolidated income statements.
Standalone Business
EIPICO registered EGP 468.95 million in standalone net profit after tax during the first six months (6M) of 2023, an annual surge from EGP 297.59 billion.
Non-consolidated revenues hiked to EGP 2.16 billion in H1-23 from EGP 1.69 billion in H1-22, while the earnings per share (EPS) increased to EGP 4.73 from EGP 3.
In the three-month period that ended on 31 March 2023, the EGX-listed firm logged consolidated net profit after tax valued at EGP 188.41 million, up from EGP 173.68 million in Q1-22, including minority interest.
